PetVivo Holdings, Inc. (OTCQX: PETV; OTC ID: PETVW), through its wholly owned subsidiary Petvivo Animal Health, a leading biomedical company delivering innovative medical devices and therapeutics for ...

Cost of revenues for the nine months ended September 30, 2025 totaled $7.9 million compared to $11.4 million in the same period last year. The decrease was primarily due to a decrease in jet card and ...

In both fatal cases, patients developed markedly elevated liver enzymes and required hospitalization within two months of Elevidys infusion. An additional serious, non-fatal case of acute liver injury ...

Leading CIOs honored for leadership, innovation, and business impact. NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The 2025 ...

America’s Top Financial Advisory Firms award received in 2026 were granted by Newsweek, with assistance from Plant-A Insights Group. McAdam LLC did not apply for or pay for the award. The ranking of ...

The Oslo, Stadt-Bond has a maturity date of 10/23/2035 and offers a coupon of 4.3700%. The payment of the coupon will take place 1,0 times per Year on the 23.10.. At the current price of 100.813 NOK ...

DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product Revenue Positive Interim ...

Investors probably aren't getting the economic data they've been missing, even with the shutdown ending. Rate-cut views for ...

CERRITOS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, ...

Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for ...

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of ...